Fewer GI Bleeds With Ticagrelor and Prasugrel After PCI Fewer GI Bleeds With Ticagrelor and Prasugrel After PCI
In a comparison of post-PCI antiplatelet medications, ticagrelor or prasugrel were associated with fewer GI bleeding events than clopidogrel.Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 26, 2020 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news
Antithrombotic Therapies in COVID-19 Disease: a Systematic Review
Conclusion(s): New evidence on thromboembolism in COVID-19 does not warrant a change in current guidance on thromboprophylaxis among hospitalized patients. Prospective trials of antithrombotic treatment strategies among patients with COVID-19 are urgently needed. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - July 1, 2020 Category: Consumer Health News Source Type: news
ACC Virtual Scientific Sessions 2020: Interventional Strategies Highlights ACC Virtual Scientific Sessions 2020: Interventional Strategies Highlights
Genetic testing for clopidogrel resistance and a new strategy for atrial fibrillation ablation are among the highlights from the virtual ACC scientific sessions.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 28, 2020 Category: Consumer Health News Tags: Cardiology News Source Type: news
Mislabeled Clopidogrel Lot Recalled, May Contain Simvastatin Mislabeled Clopidogrel Lot Recalled, May Contain Simvastatin
International Laboratories has recalled one lot of clopidogrel tablets packaged in bottles of 30 tablets because it may contain simvastatin instead of clopidogrel.News Alerts (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - April 17, 2020 Category: Cardiology Tags: Cardiology News Alert Source Type: news
TAILOR-PCI and the Role of Genotype-Guided Antiplatelet Therapy TAILOR-PCI and the Role of Genotype-Guided Antiplatelet Therapy
Investigators from the TAILOR PCI trial that used point-of-care genomic testing to identify clopidogrel nonresponders discuss the take-homes and why genotyping may be better than platelet function tests.Mayo Clinic (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - April 7, 2020 Category: Cardiology Tags: Cardiology Commentary Source Type: news
VOYAGER PAD: Clopidogrel Adds No Benefit to Rivaroxaban+Aspirin
Adding clopidogrel added no efficacy but caused additional bleeding episodes. (Source: WebMD Health)
Source: WebMD Health - April 6, 2020 Category: Consumer Health News Source Type: news
VOYAGER PAD: Clopidogrel Adds No Benefit to Rivaroxaban+Aspirin VOYAGER PAD: Clopidogrel Adds No Benefit to Rivaroxaban+Aspirin
Adding clopidogrel added no efficacy but caused additional bleeding episodes.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 3, 2020 Category: Consumer Health News Tags: Cardiology News Source Type: news
Safe to Skip Post-TAVR Clopidogrel in Patients on OAC for AF Safe to Skip Post-TAVR Clopidogrel in Patients on OAC for AF
The bleeding risk went up in such patients on oral anticoagulation who then added clopidogrel in POPULAR-TAVI, and being on OAC alone didn ' t raise ischemic risk. Some experts question its methods.Medscape Medical News (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - March 30, 2020 Category: Surgery Tags: Cardiology News Source Type: news
Clopidogrel atop rivaroxaban and aspirin shows no added benefit for PAD
(American College of Cardiology) The results of VOYAGER PAD found that people with peripheral artery disease (PAD) who took the blood thinner rivaroxaban with aspirin after undergoing lower extremity revascularization -- a procedure to treat blocked arteries in the leg -- had a significant reduction in the risk of major adverse limb and cardiovascular events when compared with those receiving aspirin alone, according to a subgroup analysis from VOYAGER PAD presented at the American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology (ACC.20/WCC). (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 30, 2020 Category: International Medicine & Public Health Source Type: news
TAILOR-PCI: Clopidogrel Genotyping Trial Narrowly Misses Endpoint TAILOR-PCI: Clopidogrel Genotyping Trial Narrowly Misses Endpoint
The trial missed its ambitious primary endpoint of a 50% reduction in cardiovascular events, but commentators felt nonetheless that it shows a clinical benefit and should change practice.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - March 28, 2020 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news
Landmark Phase 3 VOYAGER PAD Study of XARELTO ® (rivaroxaban) Plus Aspirin Shows Significant Benefit in Patients with Symptomatic Peripheral Artery Disease (PAD) after Lower-Extremity Revascularization
RARITAN, NJ, March 28, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the VOYAGER PAD study met its primary efficacy and principal safety endpoints, demonstrating the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily) plus aspirin (100 mg once daily) was superior to aspirin alone in reducing the risk of major adverse limb and cardiovascular (CV) events by 15 percent in patients with symptomatic peripheral artery disease (PAD) after lower-extremity revascularization, with similar rates of TIMI[1] major bleeding. VOYAGER PAD is the only study to show a significant benefit using...
Source: Johnson and Johnson - March 28, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news
Janssen Highlights Continued Commitment to Cardiovascular & Metabolic Healthcare Solutions with Late-Breaking Data at the First Fully Virtual American College of Cardiology Scientific Session
RARITAN, N.J., March 20, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that it will unveil late-breaking data from its leading cardiovascular and metabolism portfolio during the virtual American College of Cardiology’s 69th Annual Scientific Session together with the World Congress of Cardiology (ACC.20/WCC) on March 28-30, 2020. Notably, four late-breaking abstracts for XARELTO® (rivaroxaban) will be presented, including data from the Phase 3 VOYAGER PAD study in patients with symptomatic peripheral artery disease (PAD) after lower-extremity revascularization.Click to Tweet: Jan...
Source: Johnson and Johnson - March 20, 2020 Category: Pharmaceuticals Source Type: news
More Concern Over Morphine, Clopidogrel Interaction in ACS More Concern Over Morphine, Clopidogrel Interaction in ACS
New data suggest use of morphine delays the absorption of clopidogrel and leads to an increase in short-term cardiac ischemic events.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - January 23, 2020 Category: Cardiology Tags: Neurology & Neurosurgery News Source Type: news
Clopidogrel Appropriate for PCI in Liver Transplant Candidates Clopidogrel Appropriate for PCI in Liver Transplant Candidates
In patients with decompensated cirrhosis undergoing percutaneous coronary intervention (PCI), clopidogrel safely inhibits platelet aggregation, according to a small study of liver-transplant candidates.Reuters Health Information (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - January 8, 2020 Category: Surgery Tags: Cardiology News Source Type: news
Genetic Testing Spots Clopidogrel Responders After PCI for STEMI Genetic Testing Spots Clopidogrel Responders After PCI for STEMI
Guidelines for the management of acute STEMI patients undergoing PCI may need to be revised after a genotype-guided protocol giving clopidogrel to responders reduced bleeding rates, say experts.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 3, 2019 Category: Consumer Health News Tags: Cardiology News Source Type: news
